20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults
Author:
- 1 June 2022
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 82 (9) , 989-999
Abstract
The introduction of multi-valent pneumococcal vaccines around the world, such as the 13-valent pneumococcal conjugate vaccine (PCV13), has had a significant effect in reducing the burden of disease caused by Streptococcus pneumoniae infection globally. However, S. pneumoniae serotypes not covered by PCV13 still cause significant disease. A 20-valent pneumococcal conjugate vaccine (PCV20; Prevnar20®; Apexxnar®) has recently been licensed for active immunisation for the prevention of invasive disease and pneumonia caused by S. pneumoniae in adults. PCV20 contains all components of PCV13 with the addition of polysaccharide conjugates of seven more serotypes, selected based on their generalised geographic distribution and relative prevalence as a cause of pneumococcal disease. The immunogenicity of PCV20 in adults has been demonstrated in a well-designed program of clinical trials which showed that PCV20 administered as a single dose by intramuscular injection induced robust immune responses to all 20 S. pneumoniae serotypes covered by the vaccine. PCV20 was well tolerated, with a tolerability and safety profile similar to that for PCV13. By expanding the coverage of disease-causing S. pneumoniae serotypes relative to other PCVs, PCV20 presents a valuable new tool with the potential to further reduce the impact of pneumococcal disease.Keywords
This publication has 38 references indexed in Scilit:
- A post hoc assessment of duration of protection in CAPiTA (Community Acquired Pneumonia immunization Trial in Adults)Trials in Vaccinology, 2016
- Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in AdultsNew England Journal of Medicine, 2015
- Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillanceThe Lancet Infectious Diseases, 2015
- Recommendations for Pneumococcal Immunization Outside Routine Childhood Immunization Programs in Western EuropeAdvances in Therapy, 2014
- Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)2014
- Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adultsVaccine, 2014
- Pneumococcal infection in adults: burden of diseaseClinical Microbiology and Infection, 2014
- Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccineVaccine, 2013
- Estimating the Burden of Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis of Diagnostic TechniquesPLOS ONE, 2013
- Pneumococcal vaccine and opsonic pneumococcal antibodyJournal of Infection and Chemotherapy, 2013